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CAse repOrt
A 76-year old male presented at the Oral Medicine Clinic, 
complaining of a persistent feeling of a dry mouth, subse-
quent to having undergone surgery, chemotherapy and ra-
diation therapy for nasopharyngeal carcinoma, 18 months 
previously. Other than the cancer, he had no systemic prob-
lems of note and was otherwise in good physical health. 
Upon further questioning, the patient reported that the dry 
mouth condition was affecting his quality of life and that he 
was losing weight due to difficulty in eating. He further em-
phasised that his mouth felt dry within five minutes of rinsing 
his mouth with the palliative agents suggested by his den-
tist and oncologist. The regimen he followed to relieve his 
symptoms included glycerine BP oil, Candacide® (a nystatin 
containing product), Biotene® mouth spray and mouthrinse 
(these products contain lactoperoxidase, glucose oxidase, 
lysozyme and lactoferrin), Orbit® sugar free gum and an in-
creased frequency of water intake.
The oral examination revealed the following signs: the oral 
cavity was very dry and the examining dental mirror even 
stuck to the oral mucosa as a result; and no saliva could 
be detected in the patient's mouth even after "milking" the 
submandibular and sublingual salivary gland ducts. The 
tongue appeared erythematous and lobulated and flat ery-
thematous patches were evident on the palatal mucosa 
(Figures 1 and 2). 
Based on the history and signs, a diagnosis of erythema-
tous candidiasis associated with radiation-induced xeros-
tomia, was made. As a result, the patient was treated with 
a broad spectrum antiseptic mouthrinse of 0.2% aqueous 
solution of chlorhexidine gluconate and was encouraged 
to use the carboxymethylcellose-based artificial saliva 
supplied. The maintenance of good oral hygiene and the 
need for frequent dental evaluation to detect and correct 
early caries lesions, was emphasised. Two weeks later the 
patient reported a significant improvement and felt that the 
artificial saliva produced a prolonged moisturising effect of 
his mouth. He also stated that he was now able to eat with 
minimal discomfort.
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Oral medicine case book 53: 
Radiation-induced xerostomia
Figure 1: The patient presented with buccal mucosae appearing dull and dry
Figure 2: The tongue of the patient appeared dry with a cobble-stone ap-
pearance and with prominent papillae in the posterior third of the tongue.
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DIsCUssION 
Xerostomia, or dry mouth, is a subjective feeling or sensation 
of oral dryness and may be actual or perceived. Pathological 
xerostomia is defined as a salivary flow reduction or salivary 
hypofunction of greater than 50% and is a common compli-
cation in patients who receive radiation therapy for head and 
neck cancer.1 The radiation may cause long term irreversible 
damage to vital tissues such as salivary glands, connective 
tissues, blood vessels and bone in the radiated field.2 
Patients with head and neck cancer are often exposed to a 
total radiation dosage of between 50-70Gy.2 The tolerance 
dose for parotid salivary gland varies,3 but it is suggested 
that the serous acinar cells of the parotid gland are vulner-
able to permanent damage if the radiation dose exceeds 
60Gy.4 Radiation injury causes DNA damage, affects the cell 
cycle and can result in cell senescence and cell death. Con-
sequently, degenerated acinar cells of the salivary glands 
become dysfunctional and this leads to hypo-salivation. Dur-
ing the first week of radiation therapy, saliva production from 
the parotid and sub-mandibular glands starts to reduce and 
by six to eight weeks, saliva production is minimal.4 This has 
long-lasting effects that may continue for several months/
years, depending on the total radiation dosage received and 
the volume of irradiated tissue. Recovery of the major sali-
vary glands takes between three months and one year after 
therapy, provided the total maximum dosage did not exceed 
39Gy and where the turnover rate of acinar cells, of 60-120 
days, remains unaltered.6 On the other hand, minor salivary 
glands are more resistant to radiation therapy and they may 
play an important role in the stimulation of remaining vital 
glandular tissue, the mainstay of the treatment of radiation-
induced xerostomia. However, minor salivary glands con-
tribute less than 10% of total salivary production in the oral 
cavity and therefore cannot be expected to fully compen-
sate for the decrease in saliva production.1
Clinically, patients suffering from radiation-induced xerosto-
mia show characteristic features. The saliva may have an in-
creased viscosity, a decreased transparency and in certain 
cases, may become yellow-brown in colour.4 Extra-orally, 
these patients may suffer from dry and chapped lips whilst 
intra-orally, the common clinical features include glossy and 
dehydrated oral mucosae; a fissured, erythematous or de-
papillated tongue; and the absence of salivary pooling in the 
floor of the mouth. Clinicians should palpate the ducts of 
the major salivary glands in an attempt to express saliva, i.e. 
Stensen’s duct of the parotid gland that empties on buccal 
mucosa opposite the first upper molar, Wharton’s duct of 
the sub-mandibular gland and the duct of the sub-lingual 
gland, both the latter emptying in the region of sub-lingual 
papilla on the floor of the mouth. Xerostomia may also pre-
dispose the patient to infection of the salivary glands and a 
cloudy or purulent discharge from the salivary ducts may be 
an indication of this complication.1
consequences of xerostomia include:6,7,8 
radiation caries due to the shift of the oral microflora to 1. 
favour cariogenic bacteria indicated by an increase in 
counts of Streptococcus mutans;
decreased oral clearance due to salivary flow reduction;2. 
suscepibility to trauma and oral infections, especially 3. 
candidiasis, due to dry and atrophic oral mucosae;
difficulty with managing prosthetic appliances; 4. 
impaired normal oral function, i.e mastication, swallow-5. 
ing, speech and taste;
burning sensation that may, on occasion, lead to insomnia;6. 
halitosis;7. 
malnutrition due to dysphagia-induced decrease in 8. 
food intake.
Ideally, dental care should begin before radiation treatment 
commences and must be continued during treatment and 
post-treatment phases. It is estimated that about 58-97% of 
patients require dental care prior to radiation therapy.2,5 In the 
pre-treatment phase, patients should receive a comprehen-
sive oral assessment and management of all dental prob-
lems, e.g. dental caries, periodontal diseases, oral infections, 
defective restorations and ill-fitting dentures. Should extrac-
tion of teeth with a poor prognosis be needed, such should 
be performed two weeks prior to the commencement of ra-
diotherapy in order to avoid post-radiation complications such 
as osteo-radionecrosis. For the dentate patient, a fluoride tray 
should be constructed for the prophylactic delivery of fluoride 
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Table 1: The preventive and palliative measures for xerostomia. (RT=radiation therapy)* 
Preventive measures to manage the consequences of reduction 
of salivary flow
Palliative measures to improve moisture retention in oral cavity 
Change in dietary habits: 
reduced consumption of dry/spicy/acidic food•	
avoid beverages containing alcohol or caffeine•	
low sugar diet•	
reduced frequency of food intake •	
increased frequency of fluid intake •	
Application of topical neutral-pH sodium fluoride agents (for 
teeth remineralisation)
Apply gel once/day (with fluoride tray) or rinse twice/day 
Regular dental recall visits:
first two years: every four months post- RT•	
after two years, every six months •	
Radiographs
bitewings once/year (to detect early carious lesions) •	
panoramic once/year (to detect any bony pathoses)•	
Prophylactic antifungal therapy 
for existing oral candidasis: clotrimazole troches 10mg, one •	
troche/day).
prophylactic treatment : chlorhexidine mouthwash •	
Topical measures 
Increased frequency of water intake (frequent sips of water)
Saliva substitutes containing
carboxymethlycellulose •	
mucin•	
xanthan gum•	
polyglycerylmethacrylate•	
salivary enzymes•	
Mechanical stimulation of salivation 
sugar-free candy or chewing gum•	
acidic sweet/drinks (not ideal) •	
Acupuncture 
alternative medicine based on the concept of neuronal activa-•	
tion 
Systemic saliva stimulants/cholinergic agonist (pilocarpine): 
stimulate remaining gland function•	
use after RT completed •	
use for three months and reassess •	
* Adapted from the publication by Shiboski, Hodgson and Schiødt, 20074
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during radiation therapy and, for the edentulous patient, a split 
denture with a reservoir for artificial saliva, may be of benefit.8 
Moreover, the patient should be made aware of the impor-
tance of maintaining good oral hygiene and of regular dental 
visits to manage complications as they arise.2 Patients should 
be advised to use a soft toothbrush, gauze or mouth sponge 
to clean their mouths and the frequent use of chlorhexidine-
containing mouth rinses should be encouraged to prevent the 
development of superficial mucosal infections. In this event, 
however, the patient should be warned that the rinse will af-
fect taste and may produce tooth discolouration. Therefore, a 
watchful brief should be kept on tooth staining and the stains 
removed before they become troublesome to the patient.
The management of xerostomia may be divided into pre-
ventive and palliative measures (Table 1).1 Products availa-
ble include a range of artificial saliva products, mouth rins-
es, gels, sprays and toothpastes to help reduce symptoms 
of xerostomia. Locally available brands include Biotene® 
and Oral Balance® gel (contains xylitol and lysozyme).10 
Carboxymethlycellulose-based artificial saliva has proven 
to be effective in reducing xerostomia-related symptoms 
and reports suggest that carboxymethylcelluose-based 
products are more acceptable to patients than mucin-
containing ones.4,9 Pilocarpine, a sialogogue, is approved 
by the U.S. Food and Drug Administration for the treat-
ment of radiotherapy-induced xerostomia.1 It may be used 
after radiation therapy to directly stimulate the muscarinic 
receptors in the remaining salivary tissue.11 Pilocarpine is 
prescribed at an oral dose of 5-10mg, three times daily 
and the efficacy of the drug should be assessed after 
three months of therapy. Although pilocarpine may have 
positive effects on salivary gland stimulation, the side ef-
fects of the drug include headaches, sweating and urinary 
frequency and may limit its widespread use.6,11 The drug 
is contra-indicated in patients with gastric ulcers, hyper-
tension, narrow-angle glaucoma, acute iritis, uncontrolled 
asthma and in patients on beta-blockers and with known 
hypersensitivity.11
In the post treatment phase, the clinician should reinforce 
the importance of good oral hygiene, the maintenance of a 
healthy dentition and of regular follow-up dental visits. The 
latter will allow the opportunity to reassess plaque-control 
and to manage early radiation caries. Extractions should 
be avoided - However, when mandatory, a chlorhexidine 
mouth rinse regimen and antibiotic prophylaxis should be 
employed, before any procedure is carried out. In all cas-
es, the extraction should be performed with as little trauma 
as possible and it may be beneficial to place a splint over 
the site to prevent trauma during the post-extraction heal-
ing period.2 
CONCLUsION
Xerostomia impairs oral function and significantly impacts on 
a patient’s quality of life. Post-radiation salivary gland dys-
function is common and it is essential that the clinician rec-
ognises the problems and provides appropriate treatment 
to prevent and manage the complications associated with 
salivary hypo-function. Management of xerostomia involves 
a multi-disciplinary approach with regular dental visits and 
the use of palliative and preventative modalities of manage-
ment, as required. Salivary stimulants and substitutes are 
helpful in treating the symptoms arising from xerostomia and 
the various products can be combined in order to suit in-
dividual needs. Patients should also be made aware of the 
importance of maintaining good oral hygiene and a healthy 
dentition, as well as the benefit of adopting a long term den-
tal and oral health care programme.
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Remember to 
complete the 
CPD Questionnaire 
on page 392 and 
earn 3 CEU’s: 
1 ethical and 2 
general CEU’s.
